Daraxonrasib Doubles Survival in Landmark Metastatic Pancreatic Cancer Trial

Survival Outcomes: An Unprecedented Leap in a Difficult Setting

The trial met all of its primary and key secondary endpoints with statistical significance . The headline finding is a hazard ratio of 0.40 (p<0.0001), which represents a 60% reduction in the risk of death . This translates into a doubling of median overall survival (OS):

• Median OS (daraxonrasib): 13.2 months
• Median OS (chemotherapy): ~6.6–6.7 months

The survival benefit was not confined to a narrow genetic subgroup. A roughly doubled survival and a 60% reduction in death risk were observed both in patients with identified RAS G12 mutations and across the entire intent-to-treat (ITT) population, which included people without a detectable tumor RAS mutation . By the 12-month landmark, more than half of the patients on daraxonrasib were still alive, compared to approximately only one-quarter of those on chemotherapy .

Beyond the headline OS figure, the trial met its other key goals:

• Progression-Free Survival (PFS) and Overall Response Rate (ORR): Statistically significant improvements favoring daraxonrasib were also reported for PFS and ORR, though the press releases and initial presentation abstracts emphasize the overall survival benefit most strongly .
• Time on Treatment: Patients remained on daraxonrasib for a median of 6.2 months, compared to between 1.5 and 3.2 months across the various standard chemotherapy regimens available to the control arm, offering a rough proxy for its practical tolerability .

Safety and Tolerability: A Dramatically Different Profile from Chemotherapy

The safety profile of daraxonrasib, while not without side effects, was described as manageable and compared favorably against cytotoxic chemotherapy on the measures that matter most to patients . Crucially, no new safety signals were identified in this large Phase 3 dataset .

Head-to-Head Comparison of Key Safety Metrics

Daraxonrasib's advantage was clearest when comparing treatment-discontinuation rates and severe adverse events.

• Grade ≥3 Treatment-Related Adverse Events (TRAEs): 43.6% of patients on daraxonrasib experienced a severe TRAE, compared to 57.5% of patients on standard chemotherapy .
• Treatment Discontinuation Due to AEs: This metric represents the starkest contrast. Only 1.2% of patients in the daraxonrasib arm stopped treatment due to side effects, compared to 11.2% of patients receiving chemotherapy—a nearly 10-fold difference .

What Are the Side Effects of Daraxonrasib?

The most common side effects were largely predictable from earlier-phase studies and were predominantly low-grade, though they affected the vast majority of patients .

• Rash: Occurred in approximately 85–90% of patients .
• Diarrhea: Reported in roughly 58% of patients .
• Stomatitis (mouth sores): Experienced by about 53% of patients .

It is important to note that while these top-line numbers show a clear advantage, a nuanced view is necessary. High-grade toxicities are a reality with daraxonrasib; a single Grade 5 (fatal) case of treatment-related pneumonitis was reported . In contrast, the chemotherapy arm was associated with the expected high rates of neutropenia, peripheral neuropathy, anemia, and thrombocytopenia . Quality-of-life analyses further reinforced daraxonrasib's tolerability advantage, demonstrating a significantly delayed deterioration in pain, global health status, and overall quality of life compared to chemotherapy .

Regulatory Path: From Breakthrough Designation to Imminent Filing

Daraxonrasib has been on an accelerated regulatory trajectory for over a year. In June 2025, the U.S. Food and Drug Administration (FDA) granted it Breakthrough Therapy Designation for previously treated metastatic pancreatic cancer with KRAS G12 mutations, based on promising early-phase clinical evidence . An Orphan Drug Designation followed in October 2025 .

In January 2026, the FDA permitted Revolution Medicines to initiate an expanded access treatment protocol, providing the drug to eligible patients outside the clinical trial setting before formal approval . With the positive RASolute 302 results now fully presented, the company has announced its intention to submit a New Drug Application (NDA) to the FDA . The acceptance and review timelines for that submission have not yet been publicly reported.

Expert Reactions and Future Directions: A Standing Ovation and a New Frontline Trial

The magnitude of the achievement was unmistakable at ASCO 2026. The presentation by Dr. Brian Wolpin received a rare standing ovation from the plenary session audience, a gesture widely noted as reflecting the historic nature of the results in a cancer type where incremental progress has long been the norm . Commentators described the data as "unprecedented" and "paradigm-shifting" for the second-line treatment of metastatic pancreatic cancer, framing it as a landmark validation that RAS—long considered "undruggable"—is now a clinically meaningful drug target .

These results have already triggered the launch of RASolute 303, a global Phase 3 registrational trial that is now testing daraxonrasib as a first-line therapy for metastatic PDAC, aiming to bring this targeted approach to patients even earlier in their treatment journey .